Arcadia Biosciences, Inc. (RKDA)
NASDAQ: RKDA · Real-Time Price · USD
0.5145
+0.0245 (5.00%)
At close: Aug 26, 2026, 4:00 PM EDT
0.5145
0.00 (0.00%)
After-hours: Aug 26, 2026, 4:00 PM EDT
Arcadia Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4.75 | 4.86 | 5.05 | 4.45 | 5 | 6.78 | |
Revenue Growth | -12.22% | -3.71% | 13.27% | -10.87% | -26.30% | -15.61% |
Cost of Revenue | 3.1 | 3.11 | 2.86 | 2.07 | 2.99 | 9 |
Gross Profit | 1.64 | 1.75 | 2.18 | 2.39 | 2 | -2.22 |
Selling, General & Admin | 5.45 | 7 | 9.64 | 8.23 | 9.22 | 22.09 |
Research & Development | - | - | - | 0 | - | - |
Operating Expenses | 5.45 | 7 | 9.64 | 8.24 | 9.22 | 22.09 |
Operating Income | -3.8 | -5.25 | -7.46 | -5.85 | -7.22 | -24.31 |
Interest Expense | - | - | - | - | - | -0.02 |
Interest & Investment Income | 0.01 | 0.22 | 0.78 | 0.7 | 0.29 | - |
Other Non Operating Income (Expenses) | -3.03 | -0.05 | -1.44 | 0.09 | 2.9 | 8.07 |
EBT Excluding Unusual Items | -6.82 | -5.08 | -8.12 | -5.07 | -4.02 | -16.26 |
Merger & Restructuring Charges | - | - | - | - | - | -0.85 |
Impairment of Goodwill | - | - | - | - | - | -1.65 |
Gain (Loss) on Sale of Investments | -4.3 | - | - | - | 1.14 | 10.22 |
Gain (Loss) on Sale of Assets | - | 0.75 | 4 | 0.03 | 0.31 | -0.5 |
Asset Writedown | - | - | -0.19 | -0.28 | -1.29 | -8.43 |
Other Unusual Items | - | 2 | - | - | 0.07 | 1.33 |
Pretax Income | -11.12 | -2.33 | -4.31 | -5.32 | -3.79 | -16.13 |
Income Tax Expense | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Earnings From Continuing Operations | -11.13 | -2.34 | -4.32 | -5.33 | -3.81 | -16.13 |
Earnings From Discontinued Operations | - | - | -2.72 | -8.66 | -11.8 | - |
Net Income to Company | -11.13 | -2.34 | -7.04 | -13.99 | -15.61 | -16.13 |
Minority Interest in Earnings | - | - | - | 0.01 | 0.24 | 1.47 |
Net Income | -11.13 | -2.34 | -7.04 | -13.98 | -15.38 | -14.66 |
Net Income to Common | -11.13 | -2.34 | -7.04 | -13.98 | -15.38 | -14.66 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 1 | 1 |
Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 1 | 1 |
Shares Change | 43.17% | 0.35% | 10.22% | 106.37% | 12.66% | 113.68% |
EPS (Basic) | -5.69 | -1.71 | -5.16 | -11.30 | -25.65 | -27.56 |
EPS (Diluted) | -5.69 | -1.71 | -5.16 | -11.30 | -25.65 | -27.56 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.54 | -4.74 | -9.64 | -15.3 | -14.05 | -26.88 |
Free Cash Flow Per Share | -1.30 | -3.46 | -7.07 | -12.37 | -23.44 | -50.52 |
Gross Margin | 34.60% | 36.04% | 43.27% | 53.62% | 40.10% | -32.80% |
Operating Margin | -80.15% | -108.07% | -147.83% | -131.32% | -144.43% | -358.58% |
Profit Margin | -234.53% | -48.15% | -139.50% | -313.90% | -307.70% | -216.22% |
Free Cash Flow Margin | -53.43% | -97.55% | -191.14% | -343.49% | -281.15% | -396.39% |
EBITDA | -3.79 | -5.22 | -7.35 | -5.56 | -6.74 | -23.27 |
EBITDA Margin | -79.90% | -107.41% | -145.59% | -124.88% | -134.84% | - |
D&A For EBITDA | 0.01 | 0.03 | 0.11 | 0.29 | 0.48 | 1.05 |
EBIT | -3.8 | -5.25 | -7.46 | -5.85 | -7.22 | -24.31 |
EBIT Margin | -80.15% | -108.07% | -147.83% | -131.32% | -144.43% | - |
Revenue as Reported | 4.75 | 4.86 | 5.05 | 4.45 | 5 | 6.78 |